Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > ACADEMIA
ACADEMIA
- Decision to Prescribe Prazaxa Should Be Left to Specialists for Now: JCS Press Seminar
September 30, 2011
- 95% of Patients Favor Comprehensive Agreements to Use Tissue for Research: NCC
September 26, 2011
- JASSO to Announce New Diagnostic Guidelines for Obesity
September 26, 2011
- Insurers Favor Incentives to Pharmacies to Promote Use of Generics: Seminar
September 26, 2011
- Regulatory Science Society Holds 1st Scientific Convention
September 19, 2011
- NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
- Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
- Intensive Therapy with Rosuvastatin Effective at Inhibiting Progression of IMT: JART Study
September 12, 2011
- Apixaban Superior to Warfarin, Risk of Major Bleeding Down 30%: ESC
September 12, 2011
- 42 Nat’l Univ. Hospitals Share Drug Price Information to Reduce Purchase Costs
September 12, 2011
- NCC Aims to Become World’s Leading Early Clinical Development Center
September 12, 2011
- ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
- JCS Recommends Dabigatran in Patients with CHADS2 Score of 1
September 5, 2011
- Osaka Univ. Hospital to Lead Innovation to Discover Globally Competitive Drugs
September 5, 2011
- Univ. of Tokyo Hospital to Initiate PI Trial of Radical AD Treatments
September 5, 2011
- Keio Univ. to Begin PI Trials of New Drugs for Refractory Immunological Diseases in FY2012
September 5, 2011
- Generic Drugs Accounted for 23.1% of Drug Sales Volume in April-June: JGA
September 2, 2011
- National Cancer Center to Set Up Phase I Center by End of FY2011
September 1, 2011
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…